ArticleAmerican journal of preventive medicine2025
Social Safety Net Programs: The Relationship With Drug Treatment Among Women.
Article in American journal of preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionSocial safety net programs (e.g., Medicaid and government assistance) may facilitate drug use disorder treatment receipt. This study explored the associations of social safety net programs with drug treatment and medication for opioid use disorder receipt among women with drug use disorder and opioid use disorder, respectively.
methodsData were from the 2022 public-use National Survey on Drug Use and Health (analyzed in 2024) from women aged 18-64 years who met the criteria for past-year DSM-5 drug use disorder (n=2,784) and opioid use disorder (n=458). Odds of past-year drug use disorder treatment among women with drug use disorder and past-year medication for opioid use disorder treatment among women with opioid use disorder were estimated by government assistance and/or Medicaid receipt in primary analyses, followed by secondary categorizations of exposure (any government assistance, number of programs received), using separate logistic regressions, controlling for sociodemographics.
resultsIn primary analyses, women with drug use disorder receiving both Medicaid and government assistance were more likely to report past-year drug use disorder treatment (AOR=2.91; 95% CI=1.60, 5.29) than women receiving neither. Women with past-year opioid use disorder receiving both Medicaid and government assistance were more likely to report medication for opioid use disorder (AOR=3.41; 95% CI=1.01, 11.61) than those receiving neither. Secondary analyses results were in the same direction.
conclusionsLikelihood of drug treatment and medication for opioid use disorder receipt among women with drug use disorder and opioid use disorder, respectively, increased when Medicaid was combined with other forms of government assistance. Treatment costs and other barriers such as lack of insurance, childcare, and employment support are critical determinants of drug treatment; This study's findings suggest that government support programs may help to buffer these known barriers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.